ISSN: 2577-4379
Authors: Faiza Naeem*
Hepatitis C is triggered by the presence of hepatitis C virus (HCV) where acute and chronic hepatitis causes mild to severe illness lasting for few weeks to lifelong illness. The HCV is a bloodborne virus having most common modes of infection through exposure to even small quantities of contaminated blood and this may trigger through contaminated injection drug use, unsafe injection practices, hazardous health care, transfusion of unscreened blood or blood products and sexual practices. In 2016, WHO estimated roughly 399, 000 people died from HCV frequently from liver cirrhosis and hepatocellular carcinoma (HCC) which is primary liver cancer. Presently, there is no effective vaccine in contradiction of hepatitis C. Fever, fatigue, decreased appetite, abdominal pain and joint pain are common clinical presentations. Investigation for anti-HCV antibodies alongwith serological testing identifies individuals who have been infected with HCV. Ribavirin and sofosbuvir are the main anti-viral drugs which can treat the hepatitis C. In this case scenario, referred patient of 40 years old female is suffering from hepatitis C having severe abdominal pain along with generalized body weight. Confirmation of hepatitis C for this patient was done by anti-HCV antibodies, LFT report and ultrasound which also reveal fatty liver. Symptomatically, she was treated by antiviral drug therapy which finally stabilizes her severe abdominal pain and other clinical presentations along with the condition of hepatitis C.
Keywords: Hepatitis C; Pharmacotherapeutic Plan; Clinical Assessment; Ribavirin; Sofosbuvir
